#CRAVAT Report
#Created at Wednesday 09/07/2022 11:28:51
#Report level: variant
#
Variant Annotation																Cancer Genome Interpreter							Original Input			
UID	Chrom	Position	Ref Base	Alt Base	Note	Coding	Gene	Transcript	Sequence Ontology	cDNA change	Protein Change	All Mappings	Sample Count	Samples	Tags	Association	Biomarker	Drug	Evidence	Source	Tumor Type	All Annotations	Chrom	Pos	Reference allele	Alternate allele
1	chr14	104776711	G	T		Yes	AKT1	ENST00000349310.7	missense_variant	c.235C>A	p.Gln79Lys	ENST00000349310.7:AKT1:P31749:missense_variant:p.Gln79Lys:c.235C>A; ENST00000402615.6:AKT1:P31749:missense_variant:p.Gln79Lys:c.235C>A; ENST00000407796.6:AKT1:P31749:missense_variant:p.Gln79Lys:c.235C>A; ENST00000544168.5:AKT1::processed_transcript::; ENST00000554581.5:AKT1:P31749:missense_variant:p.Gln79Lys:c.235C>A; ENST00000554848.5:AKT1:P31749:missense_variant:p.Gln79Lys:c.235C>A; ENST00000555380.1:AKT1::processed_transcript::; ENST00000555528.5:AKT1:P31749:missense_variant:p.Gln79Lys:c.235C>A; ENST00000649815.1:AKT1:P31749:missense_variant:p.Gln79Lys:c.235C>A	0			Resistant	AKT1 (Q79K,E17K)	BRAF inhibitors	Case report	PMID:24265152	Cutaneous melanoma	[["Resistant", "AKT1 (Q79K,E17K)", "BRAF inhibitors", "Case report", "PMID:24265152", "Cutaneous melanoma", "ENST00000554581"]]	chr14	104776711	G	T
2	chr9	130873027	T	A		Yes	ABL1	ENST00000318560.6	missense_variant	c.1075T>A	p.Phe359Ile	ENST00000318560.6:ABL1:P00519:missense_variant:p.Phe359Ile:c.1075T>A; ENST00000372348.7:ABL1:P00519:missense_variant:p.Phe378Ile:c.1132T>A	0			Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	Bosutinib (BCR-ABL inhibitor  3rd gen)	NCCN guidelines	PMID:21562040	Chronic myeloid leukemia	[["Responsive", "ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)", "Bosutinib (BCR-ABL inhibitor  3rd gen)", "NCCN guidelines", "PMID:21562040", "Chronic myeloid leukemia", "ENST00000318560"], ["Responsive", "ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)", "Dasatinib (BCR-ABL inhibitor 2nd gen)", "NCCN guidelines", "PMID:21562040", "Chronic myeloid leukemia", "ENST00000318560"], ["Resistant", "ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)", "Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)", "European LeukemiaNet guidelines", "PMID:21562040", "Chronic myeloid leukemia", "ENST00000318560"], ["Resistant", "ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)", "Nilotinib (BCR-ABL inhibitor 2nd gen)", "European LeukemiaNet guidelines", "PMID:21562040", "Chronic myeloid leukemia", "ENST00000318560"]]	chr9	130873027	T	A
3	chr9	130872201	G	C		Yes	ABL1	ENST00000318560.6	missense_variant	c.895G>C	p.Val299Leu	ENST00000318560.6:ABL1:P00519:missense_variant:p.Val299Leu:c.895G>C; ENST00000372348.7:ABL1:P00519:missense_variant:p.Val318Leu:c.952G>C	0			Responsive	ABL1 (V299L)	Cabozantinib (Pan-kinase inhibitor)	Pre-clinical	PMID:26924578	Any cancer type	[["Responsive", "ABL1 (V299L)", "Cabozantinib (Pan-kinase inhibitor)", "Pre-clinical", "PMID:26924578", "Any cancer type", "ENST00000318560"], ["Responsive", "ABL1 (V299L)", "Crizotinib (ALK inhibitor)", "Pre-clinical", "PMID:26924578", "Any cancer type", "ENST00000318560"], ["Responsive", "ABL1 (V299L)", "Foretinib\u00a0 (MET inhibitor)", "Pre-clinical", "PMID:26924578", "Any cancer type", "ENST00000318560"], ["Responsive", "ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)", "Nilotinib (BCR-ABL inhibitor 2nd gen)", "NCCN guidelines", "PMID:21562040", "Chronic myeloid leukemia", "ENST00000318560"], ["Responsive", "ABL1 (V299L)", "Vandetanib (Pan-TK inhibitor)", "Pre-clinical", "PMID:26924578", "Any cancer type", "ENST00000318560"], ["Resistant", "ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)", "Dasatinib (BCR-ABL inhibitor 2nd gen)", "European LeukemiaNet guidelines", "PMID:21562040", "Chronic myeloid leukemia", "ENST00000318560"], ["Resistant", "ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)", "Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)", "European LeukemiaNet guidelines", "PMID:21562040", "Chronic myeloid leukemia", "ENST00000318560"]]	chr9	130872201	G	C
4	chr14	104780214	C	T		Yes	AKT1	ENST00000349310.7	missense_variant	c.49G>A	p.Glu17Lys	ENST00000349310.7:AKT1:P31749:missense_variant:p.Glu17Lys:c.49G>A; ENST00000402615.6:AKT1:P31749:missense_variant:p.Glu17Lys:c.49G>A; ENST00000407796.6:AKT1:P31749:missense_variant:p.Glu17Lys:c.49G>A; ENST00000554581.5:AKT1:P31749:missense_variant:p.Glu17Lys:c.49G>A; ENST00000554848.5:AKT1:P31749:missense_variant:p.Glu17Lys:c.49G>A; ENST00000555380.1:AKT1::processed_transcript::; ENST00000555528.5:AKT1:P31749:missense_variant:p.Glu17Lys:c.49G>A; ENST00000649815.1:AKT1:P31749:missense_variant:p.Glu17Lys:c.49G>A	0			Resistant	AKT1 (Q79K,E17K)	BRAF inhibitors	Case report	PMID:24265152	Cutaneous melanoma	[["Resistant", "AKT1 (Q79K,E17K)", "BRAF inhibitors", "Case report", "PMID:24265152", "Cutaneous melanoma", "ENST00000554581"], ["Responsive", "AKT1 (E17K)", "AKT inhibitors", "Pre-clinical", "PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)", "Any cancer type", "ENST00000554581"], ["Responsive", "AKT1 (E17K)", "allosteric AKT inhibitors", "Early trials", "ENA 2015 (abstract B109);PMID:28489509", "Any cancer type", "ENST00000554581"], ["Responsive", "AKT1 (E17K)", "non-allosteric AKT inhibitors", "Early trials", "ENA 2015 (abstract B109);PMID:28489509", "Any cancer type", "ENST00000554581"], ["Responsive", "AKT1 (E17K)", "PI3K pathway inhibitors", "Case report", "PMID:26763254", "Head an neck squamous", "ENST00000554581"], ["Responsive", "AKT1 (E17K)", "Tensirolimus (MTOR inhibitor)", "Early trials", "PMID:27016228", "Endometrium", "ENST00000554581"]]	chr14	104780214	C	T
#CRAVAT Report
#Created at Wednesday 09/07/2022 11:28:51
#Report level: gene
#
Variant Annotation					
Gene	Note	Number of Coding Variants	Number of Noncoding Variants	Sequence Ontology	All Sequence Ontologies
AKT1		2	0	missense_variant	missense_variant(0),processed_transcript(0)
ABL1		2	0	missense_variant	missense_variant(0)
#CRAVAT Report
#Created at Wednesday 09/07/2022 11:28:51
#Report level: sample
#
Variant Annotation	
UID	Sample
1	
2	
3	
4	
#CRAVAT Report
#Created at Wednesday 09/07/2022 11:28:51
#Report level: mapping
#
Variant Annotation			
Original Line	User Tags	UID	Input File Number
1		1	0
2		2	0
3		3	0
4		4	0
